Related Experiment Video
Updated: May 20, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Dupilumab-Induced Psoriasis in an Adolescent With Severe Atopic Dermatitis: Successful Management With Abrocitinib
Grigorios Theodosiou1,2, Åke Svensson1,2
1Department of Clinical Sciences, Lund University, Lund, Sweden.
Abstract:
Psoriasiform eruptions have been described in patients treated with dupilumab. This case report describes an adolescent with severe atopic dermatitis who developed a widespread psoriasiform dermatitis 8 months after starting dupilumab. His therapy was switched to abrocitinib resulting in near-complete resolution of the psoriatic lesions with good atopic dermatitis control. This case adds to the limited pediatric literature on dupilumab-induced psoriasis and highlights abrocitinib as an effective therapeutic alternative capable of addressing both conditions concurrently.
Related Concept Videos
Acne Infection
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
COPD: Management Using Bronchodilators and Corticosteroids